Table 3.
Clinical characteristics and outcomes in intervention group and control group patients after 3 months
| Intervention group | Control group | T-value | Sig. | |
|---|---|---|---|---|
| Mean (S.D.) | Mean (S.D.) | |||
| General overuse | 12.17 (2.19) | 12.69 (2.62) | 1.583 | 0.115 |
| General harm | 10.61 (2.37) | 10.77 (2.93) | 0.467 | 0.641 |
| Beneficial effect of pharmaceuticals | 14.91 (1.99) | 15.11 (2.15) | 0.708 | 0.480 |
| Beliefs about medicines | 36.84 (3.77) | 38.43 (4.46) | 2.855 | 0.005a |
| Sensitive | 15.40 (2.61) | 15.47 (3.11) | 0.165 | 0.869 |
| Necessity beliefs | 18.73 (3.78) | 18.46 (4.19) | 0.509 | 0.611 |
| Concern beliefs | 12.42 (3.18) | 13.25 (4.00) | 1.694 | 0.092 |
| Treatment Satisfaction Questionnaire for Medication (TSQM) | 86.68 (11.08) | 82.82 (13.40) | 2.326 | 0.021a |
| Estimated weights for EQ-5D | 0.66 (0.39) | 0.65 (0.38) | 0.076 | 0.939 |
| Montgomery–Åsberg Depression Scale | 21.07 (12.21) | 21.01 (12.63) | 0.036 | 0.971 |
| Medication Adherence Scale | 5.79 (1.89) | 5.04 (1.98) | 2.880 | 0.004a |
aSignificantly different